• 1. An artificial photosynthetic system for photoaccumulation of two electrons on a fused dipyridophenazine (dppz)–pyridoquinolinone ligand?
  Philipp Traber,Stephan Kupfer,Stefanie Gr?fe,Isabelle Baussanne,Martine Demeunynck,Jean-Marie Mouesca,Serge Gambarelli,Vincent Artero,Murielle Chavarot-Kerlidou Chem. Sci., 2018,9, 4152-4159
• 2. An integrated microfluidic 3D tumor system for parallel and high-throughput chemotherapy evaluation?
  Dan Liu,Rui Hu,Zhongchao Huang,Meilin Sun,Kai Han Analyst, 2020,145, 6447-6455
• 3. An approach to asymmetric synthesis of β-aryl alanines by Pd(0)-catalyzed cross-coupling and cyanate-to-isocyanate rearrangement?
  Piotr Szcze?niak,Sebastian Stecko RSC Adv., 2015,5, 30882-30888
• 4. Alumina grafted SBA-15 sustainable bifunctional catalysts for direct cross-coupling of benzylic alcohols to diarylmethanes?
  Chandran Rajendran,Govindaswamy Satishkumar,Charlotte Lang,Eric M. Gaigneaux Catal. Sci. Technol., 2020,10, 2583-2592
• 5. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941

• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes Naphthalenes
• Solvents and Organic Chemicals Organic Compounds Benzenoids Naphthalenes
• Catalysts and Inorganic Chemicals Catalysts

Research Brief on (R)-6,6'-Dibromo-2,2'-bis(methoxymethoxy)-1,1'-binaphthyl (CAS: 179866-74-1) in Chemical Biology and Pharmaceutical Applications

The compound (R)-6,6'-Dibromo-2,2'-bis(methoxymethoxy)-1,1'-binaphthyl (CAS: 179866-74-1) has garnered significant attention in recent years due to its versatile applications in asymmetric synthesis, catalysis, and pharmaceutical research. This binaphthyl derivative, characterized by its chiral backbone and brominated aromatic rings, serves as a key intermediate in the synthesis of complex molecules and ligands for transition-metal catalysts. Recent studies have explored its role in enantioselective transformations and its potential as a building block for bioactive compounds.

In a 2023 study published in the Journal of Organic Chemistry, researchers demonstrated the utility of (R)-6,6'-Dibromo-2,2'-bis(methoxymethoxy)-1,1'-binaphthyl as a precursor for chiral phosphine ligands. These ligands were employed in palladium-catalyzed asymmetric allylic alkylations, achieving enantiomeric excesses of up to 98%. The study highlighted the compound's structural robustness and its ability to induce high levels of stereocontrol in C-C bond-forming reactions, making it valuable for pharmaceutical synthesis where chirality is critical.

Another significant advancement was reported in ACS Catalysis (2024), where the compound was functionalized to create a novel class of axially chiral N-heterocyclic carbene (NHC) ligands. These ligands exhibited exceptional activity in gold(I)-catalyzed cyclization reactions, enabling the efficient synthesis of polycyclic scaffolds found in natural products with anticancer properties. The research underscored the compound's adaptability for designing next-generation catalysts with tailored steric and electronic properties.

From a pharmaceutical perspective, (R)-6,6'-Dibromo-2,2'-bis(methoxymethoxy)-1,1'-binaphthyl has shown promise in drug discovery. A 2024 Nature Communications paper detailed its use as a core structure for developing selective kinase inhibitors. Through structure-activity relationship (SAR) studies, derivatives of this compound exhibited nanomolar potency against CDK8/19, targets implicated in oncology and inflammatory diseases. The methoxymethoxy groups were found to enhance solubility while maintaining target engagement, addressing a common challenge in drug design.

Ongoing research (ChemMedChem, 2024) is investigating the compound's potential in PROTAC (Proteolysis Targeting Chimera) development. Its rigid binaphthyl scaffold serves as an ideal linker to connect E3 ligase binders with target protein ligands, enabling selective degradation of disease-causing proteins. Preliminary data show improved pharmacokinetic profiles compared to linear linkers, suggesting broad applicability in targeted protein degradation therapies.

In conclusion, (R)-6,6'-Dibromo-2,2'-bis(methoxymethoxy)-1,1'-binaphthyl continues to be a molecule of high interest across multiple disciplines. Its unique structural features enable diverse applications ranging from asymmetric catalysis to drug discovery, with recent studies pushing the boundaries of its utility. Future research directions may explore its incorporation into materials science and its potential in addressing emerging therapeutic challenges.

• 142010-87-5((S)-3,3'-Dibromo-2,2'-bis(methoxymethoxy)-1,1'-binaphthyl)
• 389867-61-2(1,1'-Binaphthalene,6,6'-dibromo-2,2'-bis(methoxymethoxy)-)
• 173831-50-0((R)-2,2’-Bis(methoxymethoxy)-1,1'-binaphthyl)
• 499783-23-2(1,1'-Binaphthalene, 6-bromo-2,2'-bis(methoxymethoxy)-)
• 142128-92-5((S)-2,2'-Bis(methoxymethoxy)-1,1'-binaphthyl)
• 211560-97-3((S)-6,6'-Dibromo-2,2'-bis(methoxymethoxy)-1,1'-binaphthalene)
• 651027-96-2([1,1'-Binaphthalen]-2-ol, 2'-(methoxymethoxy)-6,6'-diphenyl-, (1S)-)
• 117745-45-6(1,1'-Binaphthalene, 6,6'-dibromo-2,2'-dimethoxy-, (1R)-)
• 117745-41-2(1,1'-Binaphthalene, 6,6'-dibromo-2,2'-dimethoxy-, (1S)-)
• 211734-49-5((R)-3,3'-Dibromo-2,2'-bis(methoxymethoxy)-1,1'-binaphthyl)